Skip to content

Study · Randomized controlled trial · n = 40 · 1989

4 results

Nonathymulin treatment of multiple sclerosis: double-blind pilot study.

Roullet E, Cesaro P, Simon-Lavoine N, Degos JD, Marteau R

Acta neurologica Scandinavica1 Dec 1989

PMID2618585 (opens in a new tab)DOI10.1111/j.1600-0404.1989.tb03929.x (opens in a new tab)PepBankPUB-02618585
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with evolutive multiple sclerosis and moderate disability, Nonathymulin did not significantly change Kurtzke disability scores versus placebo.

    In plain wordsIn patients with multiple sclerosis, Nonathymulin did not significantly change disability scores compared with placebo.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeKurtzke disability scores
    Study

    n = 40

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference in treatment and control groups in the Kurtzke. Disability scores, Ambulation Index and Functional Scale.
    2 context sentences
    Summary · context
    We carried out a randomized, double-blind, placebo-controlled trial of Nonathymulin (NT, synthetic serum thymic factor) in patients with evolutive multiple sclerosis (MS) and moderate disability.
    Summary · context
    Forty matched patients were treated with subcutaneous NT or placebo for 6 months and followed for another 6 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with evolutive multiple sclerosis and moderate disability, Nonathymulin did not significantly change the Ambulation Index versus placebo.

    In plain wordsIn patients with multiple sclerosis, Nonathymulin did not significantly change the walking index compared with placebo.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeAmbulation Index
    Study

    n = 40

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference in treatment and control groups in the Kurtzke. Disability scores, Ambulation Index and Functional Scale.
    2 context sentences
    Summary · context
    We carried out a randomized, double-blind, placebo-controlled trial of Nonathymulin (NT, synthetic serum thymic factor) in patients with evolutive multiple sclerosis (MS) and moderate disability.
    Summary · context
    Forty matched patients were treated with subcutaneous NT or placebo for 6 months and followed for another 6 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with evolutive multiple sclerosis and moderate disability, Nonathymulin did not significantly change the Functional Scale versus placebo.

    In plain wordsIn patients with multiple sclerosis, Nonathymulin did not significantly change the function scale compared with placebo.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeFunctional Scale
    Study

    n = 40

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference in treatment and control groups in the Kurtzke. Disability scores, Ambulation Index and Functional Scale.
    2 context sentences
    Summary · context
    We carried out a randomized, double-blind, placebo-controlled trial of Nonathymulin (NT, synthetic serum thymic factor) in patients with evolutive multiple sclerosis (MS) and moderate disability.
    Summary · context
    Forty matched patients were treated with subcutaneous NT or placebo for 6 months and followed for another 6 months.
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with multiple sclerosis, the Nonathymulin trial recorded no significant side effects.

    In plain wordsIn patients with multiple sclerosis, the Nonathymulin trial recorded no significant side effects.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    Direction not reportedSignificant side effects
    Study

    n = 40

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    No significant side effects were recorded.
    2 context sentences
    Summary · context
    We carried out a randomized, double-blind, placebo-controlled trial of Nonathymulin (NT, synthetic serum thymic factor) in patients with evolutive multiple sclerosis (MS) and moderate disability.
    Summary · context
    Forty matched patients were treated with subcutaneous NT or placebo for 6 months and followed for another 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.